Clinical trial

Exercise and Dietary Lifestyle Intervention on Reducing Atrial Fibrillation Burden, Cardiac and Body Fat Mass.

Recruiting now · Not applicable · 1 countries · Registry ID NCT07430007

Recruiting nowNot applicableInterventional

What this study is about

Atrial fibrillation (AF) is the most common cardiac arrhythmia and is strongly associated with obesity and excess body fat. Lifestyle interventions, including exercise and dietary modification, may reduce AF burden, but long-term randomized controlled trial evidence with objective AF burden assessment and advanced cardiac imaging is limited. The MOVE-AF trial is a randomized controlled trial designed to evaluate whether a 12-month tailored exercise and dietary lifestyle intervention, compared with usual care, reduces atrial fibrillation burden and symptom severity and decreases cardiac and total body fat mass in overweight and obese adults with paroxysmal or persistent AF.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to 75 Years
SexAll
Healthy volunteersAccepted
ConditionAtrial Fibrillation (AF), Obesity & Overweight

Full registry criteria

Inclusion Criteria: * Age 18-75 years * Body mass index (BMI) ≥27 kg/m² * Documented atrial fibrillation (paroxysmal or persistent) * Ability to participate in exercise training and follow study procedures * Access to a smartphone or device enabling rhythm monitoring * Provides written informed consent Exclusion Criteria: * Permanent atrial fibrillation * Unstable angina pectoris or acute coronary syndrome within the past 3 months * Participation in other lifestyle or drug weight reduction trials * Significant left ventricular dysfunction (ejection fraction \<30%) * Severe valvular heart disease or planned cardiac surgery * Severe heart failure (NYHA class IV) or severe angina (CCS class IV) * Unstable coronary artery disease or recent myocardial infarction * Severe pulmonary disease limiting exercise capacity * Active malignancy * Autoimmune or systemic inflammatory diseases * Severe renal or hepatic failure * Memory disease or significant cognitive impairment * Unstable psychiatric condition * Recent joint or back surgery within the past 6 months * Continuing back or joint pain symptoms and inability to take part in individualized exercise training * Contraindications to exercise testing or training, including cardiac symptoms or cardiovascular symptoms, making exercise unsafe * Pregnancy or breastfeeding * Participation in another interventional study * Any condition judged by investigators to make participation unsafe or infeasible

Treatments and study arms

Tailored Exercise and Dietary Lifestyle Program

Behavioral

A 12-month tailored lifestyle program combining individualized aerobic exercise, muscle strength training, and dietary counseling. The program includes home-based aerobic training 2-5 times per week, muscle strength training, group-based dietary intervention sessions, and motivational support. The intervention is added to standard clinical care for atrial fibrillation.

Usual Clinical Care

Other

Participants receive standard clinical care for atrial fibrillation according to the guideline-based routine practice at participating hospitals. No structured exercise or dietary lifestyle intervention is provided.

Primary outcomes

Atrial Fibrillation Burden12 months

Total atrial fibrillation burden measured by continuous rhythm monitoring over the intervention period. Unit of Measure: Percentage of time in atrial fibrillation (%)

Study locations

4 locations were listed when this page was built. The first 40 are shown.

Hospital Nova of Central Finland🇫🇮 Jyväskylä, Central Finland, Finland
Jari Laukkanen, MD, PhDContact
Merja Perhonen, MD, PhDContact
Merja Perhonen, MD, PhDSub Investigator
Kuopio University Hospital🇫🇮 Kuopio, Northern Savonia, Finland
Marja Hedman, MD, PhDContact
Sudhir Kurl, MD, PhDContact
University of Eastern Finland🇫🇮 Kuopio, Eastern Finland, Finland
Jari Laukkanen, MD, PhDContact
Merja Perhonen, MD, PhDContact
Sudhir Kurl, MD, PhDSub Investigator
Tampere University Hospital🇫🇮 Tampere, Finland
Jussi Hernesniemi, MD, PhDContact
Kerttu Toivo, MD, PhDContact